As of Aug 17
| -0.55 / -3.44%|
The 8 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 16.00, with a high estimate of 26.00 and a low estimate of 6.00. The median estimate represents a +3.56% increase from the last price of 15.45.
The current consensus among 8 polled investment analysts is to Hold stock in Momenta Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.